Literature DB >> 11768582

Acceptability of a new modular protein substitute for the dietary treatment of phenylketonuria.

F J Rohr1, A W Munier, H L Levy.   

Abstract

The major source of protein in the dietary treatment of phenylketonuria(PKU) is a phenylalanine-free amino acid mixture. Traditionally, these medical products have also contained other nutrients and have been in powder form. However, their disagreeable taste and odour, the large volume required to provide sufficient protein and the inconvenience of their preparation and storage have hindered compliance with consumption among adolescents and adults. We studied the acceptability of a new medical product for the treatment of PKU. This product, Phlexy-10 (SHS North America, Gaithersburg, MD, USA), is available in three forms: sachets of premeasured powder to be constituted as a drink, fruit-flavoured bars and prefilled capsules. A vitamin-mineral mixture is separately provided. The forms are interchangeable because each component (one sachet, one bar or 20 capsules) provides 10g of amino acids. Since the product is primarily a source of amino acids, protein requirements can be met using a smaller volume than with traditional medical products. Eleven subjects enrolled in a 24-week trial that included clinical and laboratory evaluations. Nine subjects completed the study and 8 remained on the Phlexy-10 after the study. The powder drink was the favourite module used. One-third of the subjects included the bars and another third included the capsules in their regimens. The vitamin-mineral mixture was the least acceptable component. Mean weekly blood phenylalanine decreased by 40% from mean baseline levels. Blood concentrations of vitamins and minerals were normal except for a low zinc concentration in two subjects and a low vitamin B12 concentration in another. The lower caloric content and the separate vitamin-mineral mixture require careful monitoring of these nutrients. Phlexy-10 appears to be an adequate medical product for the treatment of PKU. Its convenience, flexibility of form and improved taste are appealing to many individuals on diet for PKU.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11768582     DOI: 10.1023/a:1012754724708

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  10 in total

1.  A SIMPLE PHENYLALANINE METHOD FOR DETECTING PHENYLKETONURIA IN LARGE POPULATIONS OF NEWBORN INFANTS.

Authors:  R GUTHRIE; A SUSI
Journal:  Pediatrics       Date:  1963-09       Impact factor: 7.124

2.  Treatment products and approaches for phenylketonuria: improved palatability and flexibility demonstrate safety, efficacy and acceptance in US clinical trials.

Authors:  A P Prince; M P McMurray; N R Buist
Journal:  J Inherit Metab Dis       Date:  1997-08       Impact factor: 4.982

3.  Management of phenylketonuria for optimal outcome: a review of guidelines for phenylketonuria management and a report of surveys of parents, patients, and clinic directors.

Authors:  R Wappner; S Cho; R A Kronmal; V Schuett; M R Seashore
Journal:  Pediatrics       Date:  1999-12       Impact factor: 7.124

4.  Rapid diagnosis of phenylketonuria by quantitative analysis for phenylalanine and tyrosine in neonatal blood spots by tandem mass spectrometry.

Authors:  D H Chace; D S Millington; N Terada; S G Kahler; C R Roe; L F Hofman
Journal:  Clin Chem       Date:  1993-01       Impact factor: 8.327

5.  Necessity of complete intake of phenylalanine-free amino acid mixture for metabolic control of phenylketonuria.

Authors:  G P Duran; F J Rohr; A Slonim; F Güttler; H L Levy
Journal:  J Am Diet Assoc       Date:  1999-12

6.  Nutrient intake and food consumption of adolescents and young adults with phenylketonuria.

Authors:  B Schulz; H J Bremer
Journal:  Acta Paediatr       Date:  1995-07       Impact factor: 2.299

7.  The use of gelatin capsules for ingestion of formula in dietary treatment of maternal phenylketonuria.

Authors:  H H Kecskemethy; D Lobbregt; H L Levy
Journal:  J Inherit Metab Dis       Date:  1993       Impact factor: 4.982

8.  A new amino acid mixture permits new approaches to the treatment of phenylketonuria.

Authors:  N R Buist; A P Prince; K L Huntington; J M Tuerck; D D Waggoner
Journal:  Acta Paediatr Suppl       Date:  1994-12

9.  Dependence of the utilization of a phenylalanine-free amino acid mixture on different amounts of single dose ingested. A case report.

Authors:  M E Herrmann; H G Brösicke; M Keller; E Mönch; H Helge
Journal:  Eur J Pediatr       Date:  1994-07       Impact factor: 3.183

10.  Reinstitution of diet therapy in PKU patients from twenty-two US clinics.

Authors:  V E Schuett; E S Brown; K Michals
Journal:  Am J Public Health       Date:  1985-01       Impact factor: 9.308

  10 in total
  4 in total

Review 1.  Nutritional issues in treating phenylketonuria.

Authors:  François Feillet; Carlo Agostoni
Journal:  J Inherit Metab Dis       Date:  2010-02-12       Impact factor: 4.982

Review 2.  New innovations: therapeutic opportunities for intellectual disabilities.

Authors:  Jonathan D Picker; Christopher A Walsh
Journal:  Ann Neurol       Date:  2013-09       Impact factor: 10.422

3.  Long-term developmental progression in infants and young children taking sapropterin for phenylketonuria: a two-year analysis of safety and efficacy.

Authors:  Nicola Longo; Komudi Siriwardena; Annette Feigenbaum; David Dimmock; Barbara K Burton; Sylvia Stockler; Susan Waisbren; William Lang; Elaina Jurecki; Charlie Zhang; Suyash Prasad
Journal:  Genet Med       Date:  2014-09-18       Impact factor: 8.822

4.  Status of nutrients important in brain function in phenylketonuria: a systematic review and meta-analysis.

Authors:  Gina A Montoya Parra; Rani H Singh; Aysun Cetinyurek-Yavuz; Mirjam Kuhn; Anita MacDonald
Journal:  Orphanet J Rare Dis       Date:  2018-06-26       Impact factor: 4.123

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.